Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases

Molecular Pharmacology

Volumn 79, Issue 1, 2011, Pages 197-206

  Huang, Po Hsien ^a   Chen, Chun Han ^a,b   Chou, Chih Chien ^a   Sargeant, Aaron M ^a   Kulp, Samuel K ^a   Teng, Che Ming ^b   Byrd, John C ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AR 42; ENTINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE H3 LYSINE 4 DEMETHYLASE; JUMONJI AT RICH INTERACTIVE DOMAIN 1C; JUMONJI T RICH INTERACTIVE DOMAIN 1B; KRUPPEL LIKE FACTOR 4; LYSINE SPECIFIC DEMETHYLASE; N HYDROXY 4 (3 METHYL 2 PHENYLBUTYRYLAMINO)BENZAMIDE; RETINOBLASTOMA BINDING PROTEIN 2; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; UVOMORULIN; VORINOSTAT;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL VIABILITY; DOWN REGULATION; DRUG EFFECT; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE METHYLATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; UPREGULATION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; DNA METHYLATION; HISTONE DEACETYLASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES, N-DEMETHYLATING; TRANSCRIPTION, GENETIC;

EID: 78651289082     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.067702     Document Type: Article

References (40)

1. Agger K, Christensen J, Cloos PA, and Helin K (2008) The emerging functions of histone demethylases. Curr Opin Genet Dev 18:159-168.
2. Agoulnik I and Weigel N (2009) Coregulators and regulation of androgen receptor action in prostate cancer, in Androgen Action in Prostate Cancer (Tindall D and Mohler J eds) pp 315-340, Springer-Verlag, New York.
3. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, et al. (2007) New nomenclature for chromatin-modifying enzymes. Cell 131:633-636.
4. Barrett A, Santangelo S, Tan K, Catchpole S, Roberts K, Spencer-Dene B, Hall D, Scibetta A, Burchell J, Verdin E, et al. (2007) Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer 121:265-275.
5. Baylin SB and Ohm JE (2006) Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107-116.
6. Brumbaugh J, Phanstiel D, and Coon JJ (2008) Unraveling the histone's potential: a proteomics perspective. Epigenetics 3:254-257.
7. Catteau A, Rosewell I, Solomon E, and Taylor-Papadimitriou J (2004) A short region of the promoter of the breast cancer associated PLU-1 gene can regulate transcription In Vitro and in vivo. Int J Oncol 25:5-16.
8. Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, and Chen CS (2007) Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 67:5318-5327.
9. Chen CS, Weng SC, Tseng PH, Lin HP, and Chen CS (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280:38879-38887.
10. Christensen J, Agger K, Cloos PA, Pasini D, Rose S, Sennels L, Rappsilber J, Hansen KH, Salcini AE, and Helin K (2007) RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell 128:1063-1076.
11. Cloos PA, Christensen J, Agger K, and Helin K (2008) Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev 22:1115-1140.
12. Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, and Timmers HT (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66:4929-4935.
13. Govind CK, Zhang F, Qiu H, Hofmeyer K, and Hinnebusch AG (2007) Gcn5 promotes acetylation, eviction, and methylation of nucleosomes in transcribed coding regions. Mol Cell 25:31-42.
14. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439-3443.
15. Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, and Chen CS (2009) alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 30:1125-1131.
16. Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH, Whetstine JR, Bonni A, Roberts TM, and Shi Y (2007) The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 128:1077-1088.
17. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, et al. (2006) Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66:11341-11347.
18. Kim DH, Lee J, Lee B, and Lee JW (2009) ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Mol Endocrinol 23:1556-1562.
19. Kulp SK, Chen CS, Wang DS, Chen CY, and Chen CS (2006) Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 12:5199-5206.
20. Latham JA and Dent SY (2007) Cross-regulation of histone modifications. Nat Struct Mol Biol 14:1017-1024.
21. Lee MG, Wynder C, Bochar DA, Hakimi MA, Cooch N, and Shiekhattar R (2006) Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol 26:6395-6402.
22. Lee MG, Wynder C, Cooch N, and Shiekhattar R (2005) An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437:432-435.
23. Lennartsson A and Ekwall K (2009) Histone modification patterns and epigenetic codes. Biochim Biophys Acta 1790:863-868.
24. Lim S, Janzer A, Becker A, Zimmer A, Schüle R, Buettner R, and Kirfel J (2010) Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 31:512-520.
25. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, et al. (2010) Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17:333-347.
26. Liu S, Zhang H, Zhu L, Zhao L, and Dong Y (2008) Kruppel-like factor 4 is a novel mediator of selenium in growth inhibition. Mol Cancer Res 6:306-313.
27. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
28. Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AH, Günther T, Buettner R, and Schüle R (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437:436-439.
29. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, and Hess JL (2002) MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10:1107-1117.
30. Nightingale KP, Gendreizig S, White DA, Bradbury C, Hollfelder F, and Turner BM (2007) Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 282:4408-4416.
31. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, and Pili R (2007) Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 67:1182-1193.
32. Ruthenburg AJ, Allis CD, and Wysocka J (2007) Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell 25:15-30.
33. Sargeant AM, Rengel RC, Kulp SK, Klein RD, Clinton SK, Wang YC, and Chen CS (2008) OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 68:3999-4009.
34. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, et al. (2009) Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res 69:2065-2071.
35. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, and Kurdistani SK (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262-1266.
36. Shilatifard A (2008) Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol 20:341-348.
37. Sims RJ, 3rd, Nishioka K, and Reinberg D (2003) Histone lysine methylation: a signature for chromatin function. Trends Genet 19:629-639.
38. Trojer P and Reinberg D (2006) Histone lysine demethylases and their impact on epigenetics. Cell 125:213-217.
39. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, and Zhang Y (2007) PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 25:801-812.
40. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, McQueen P, Atreya D, Xie J, Simoneau AR, et al. (2010) The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 9:162.